Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 14, 2017, by Ultragenyx Pharmaceutical Inc. The report details a material definitive agreement entered into on the same date regarding the sale of a regulatory asset.
Key Financial Metrics
The filing discloses a specific transaction value but does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the period.
- Transaction Value: $130,000,000
- Asset Sold: Rare Pediatric Disease Priority Review Voucher (PRV)
- Counterparty: Novartis Pharma AG
Material Changes
The primary material change is the execution of an Asset Purchase Agreement to sell the PRV awarded by the U.S. Food and Drug Administration in connection with the approval of Mepsevii (vestronidase alfa-vjbk). The sale is subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period.
Outlook, Risks, and Contingencies
The receipt of the $130,000,000 payment is contingent upon the closing of the transaction. The filing notes that the agreement contains customary representations, warranties, and covenants. No specific forward-looking guidance or risk factors beyond the standard closing conditions are detailed in this specific report.
Investor Verification Checklist
- Confirm the final closing date of the PRV sale with Novartis Pharma AG.
- Verify the expiration of the Hart-Scott-Rodino waiting period to ensure no regulatory delays.
- Review the full Asset Purchase Agreement (to be filed as an exhibit to the 2017 Form 10-K) for specific covenants.
- Monitor the company's subsequent 10-K filing for the actual recognition of the $130 million gain and its impact on the balance sheet.